Volume | 3,398,958 |
|
|||||
News | - | ||||||
Day High | 11.65 | Low High |
|||||
Day Low | 11.16 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.50 | 11.16 | 11.65 | 11.54 | 11.71 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
26,342 | 3,398,958 | $ 11.40 | $ 38,741,405 | - | 3.21 - 18.33 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:37 | formt | 299 | $ 11.65 | USD |
Iovance Biotherapeutics (IOVA) Options Flow Summary
Iovance Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.22B | 279.31M | - | 1.19M | -444.04M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iovance Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.68 | 12.14 | 11.01 | 11.58 | 3,636,602 | -0.03 | -0.26% |
1 Month | 14.12 | 15.18 | 11.01 | 12.80 | 4,324,664 | -2.47 | -17.49% |
3 Months | 7.88 | 18.33 | 7.60 | 13.89 | 9,213,241 | 3.77 | 47.84% |
6 Months | 4.00 | 18.33 | 3.47 | 10.44 | 8,293,313 | 7.65 | 191.25% |
1 Year | 5.68 | 18.33 | 3.21 | 8.80 | 7,150,140 | 5.97 | 105.11% |
3 Years | 31.73 | 33.55 | 3.21 | 10.68 | 4,456,453 | -20.08 | -63.28% |
5 Years | 10.90 | 54.2081 | 3.21 | 14.32 | 3,298,327 | 0.75 | 6.88% |
Iovance Biotherapeutics Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. |